Phase 2 N=64 Randomized Quadruple-blind Treatment

E3 Breast Cancer Taxotere Combination

Advanced Breast Cancer

Bottom Line

View on ClinicalTrials.gov: NCT00494481 ↗

Enrolled (actual)

Serious AEs

41.9%

Results posted

May 2011

Primary outcome: Primary: Number of Patients With a Disease Progression Event — 24; 18 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Vandetanib (ZD6474) (Drug); Docetaxel (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: Female
Sponsor: Genzyme, a Sanofi Company
Primary completion: Jun 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Patients With a Disease Progression Event	24; 18	—

Summary

To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology

Eligibility Criteria

Inclusion Criteria

Females with histological/cytological confirmation of breast cancer.
Subjects with a measurable lesion or bone lesions

Exclusion Criteria

Previous radiotherapy within 6 weeks
Significant cardiac events, arrhythmias or other cardiac conditions

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00494481). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.